Options for local implementation
Biosimilar medicines have the potential to offer the NHS considerable cost savings and widen the access to innovative medicines, therefore providing increased value for money. The NHS is currently engaged in many activities that have already provided greater access to biosimilars for people with serious conditions.
If such plans are not already in place, organisations should develop and agree local policies to be aware when biosimilar medicines are coming to market and then support their managed introduction into care pathways. This should be done safely and effectively, taking into account relevant regulatory advice, national guidance, patient factors and cost.
Review and, if appropriate, optimise prescribing of medicines for which biosimilar medicines exist to ensure it is in line with these policies.
Ensure all biological medicines, including biosimilar medicines, are prescribed by brand name so that products cannot be automatically substituted at the point of dispensing. The choice of whether a patient receives a biosimilar or originator biological medicine rests with the responsible clinician in consultation with the patient.